INTRODUCTION: A growing number of studies have found evidence that anxiety and depressive disorders are associated with atypical amygdala hyperactivation, which decreases with effective treatment. Interest has emerged in this phenomenon as a possible biological marker for individuals who are likely to benefit from tailored treatment approaches. OBJECTIVE: The present study was designed to examine relationships between pretreatment amygdala activity and treatment response in a sample of anxious children and adolescents. MATERIALS AND METHODS: Participants, who were diagnosed predominantly with generalized anxiety disorder (GAD), underwentfunctional magnetic resonance imaging (fMRI) scanning before treatment with fluoxetine or cognitive behavioral therapy (CBT). RESULTS: Results indicated significant negative associations between degree of left amygdala activation and measures of posttreatment symptom improvement in the group, as a whole. DISCUSSION: Taken together with research on associations between adult amygdala activation and treatment response, these findings suggest that patients whose pretreatment amygdala activity is the strongest may be particularly likely to respond well to such widely used treatments as selective serotonin reuptake inhibitor (SSRI) medications and CBT.
RCT Entities:
INTRODUCTION: A growing number of studies have found evidence that anxiety and depressive disorders are associated with atypical amygdala hyperactivation, which decreases with effective treatment. Interest has emerged in this phenomenon as a possible biological marker for individuals who are likely to benefit from tailored treatment approaches. OBJECTIVE: The present study was designed to examine relationships between pretreatment amygdala activity and treatment response in a sample of anxious children and adolescents. MATERIALS AND METHODS:Participants, who were diagnosed predominantly with generalized anxiety disorder (GAD), underwent functional magnetic resonance imaging (fMRI) scanning before treatment with fluoxetine or cognitive behavioral therapy (CBT). RESULTS: Results indicated significant negative associations between degree of left amygdala activation and measures of posttreatment symptom improvement in the group, as a whole. DISCUSSION: Taken together with research on associations between adult amygdala activation and treatment response, these findings suggest that patients whose pretreatment amygdala activity is the strongest may be particularly likely to respond well to such widely used treatments as selective serotonin reuptake inhibitor (SSRI) medications and CBT.
Authors: R C Gur; J D Ragland; P J Moberg; T H Turner; W B Bilker; C Kohler; S J Siegel; R E Gur Journal: Neuropsychopharmacology Date: 2001-11 Impact factor: 7.853
Authors: K M Thomas; W C Drevets; R E Dahl; N D Ryan; B Birmaher; C H Eccard; D Axelson; P J Whalen; B J Casey Journal: Arch Gen Psychiatry Date: 2001-11
Authors: D A Brent; D J Kolko; B Birmaher; M Baugher; J Bridge; C Roth; D Holder Journal: J Am Acad Child Adolesc Psychiatry Date: 1998-09 Impact factor: 8.829
Authors: Christopher S Monk; Eric E Nelson; Erin B McClure; Karin Mogg; Brendan P Bradley; Ellen Leibenluft; R James R Blair; Gang Chen; Dennis S Charney; Monique Ernst; Daniel S Pine Journal: Am J Psychiatry Date: 2006-06 Impact factor: 18.112
Authors: John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe Journal: JAMA Date: 2004-08-18 Impact factor: 56.272
Authors: Lauren K White; Stefanie Sequeira; Jennifer C Britton; Melissa A Brotman; Andrea L Gold; Erin Berman; Kenneth Towbin; Rany Abend; Nathan A Fox; Yair Bar-Haim; Ellen Leibenluft; Daniel S Pine Journal: Am J Psychiatry Date: 2017-04-14 Impact factor: 18.112
Authors: Riju Ray; James Loughead; Ze Wang; John Detre; Edward Yang; Ruben Gur; Caryn Lerman Journal: Behav Brain Res Date: 2008-06-05 Impact factor: 3.332
Authors: Andrea L Gold; Elizabeth R Steuber; Lauren K White; Jennifer Pacheco; Jessica F Sachs; David Pagliaccio; Erin Berman; Ellen Leibenluft; Daniel S Pine Journal: Neuropsychopharmacology Date: 2017-04-24 Impact factor: 7.853
Authors: Silvia B Bonelli; Robert Powell; Mahinda Yogarajah; Pamela J Thompson; Mark R Symms; Matthias J Koepp; John S Duncan Journal: Epilepsia Date: 2008-08-19 Impact factor: 5.864